Ανδρέας Β. Κόκκας ¹, Κωνσταντίνος Λ. Παπαδόπουλος ²

¹ Χειρούργος Οδοντίατρος ² Αν. Καθηγητής Καρδιολογίας, Διευθυντής της  Β’ Καρδιολογικής Κλινικής του Ιατρικού Τμήματος του ΑΠΘ

Α.Β. Kokkas, C.L.Papadopoulos

–

2. Stryer L.: Biochemistry. Freeman W. Co., N.Y., 1995

3. Τoschi V., Gallo R., Lettino M.: Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. Circulation 95: 594-599 (1997)

4. Guyton A., Hall J.: Textbook of Medical Physiology. Saunders W. Company, London, 1996

5. Τρακατέλλης Α.: Βιοχημεία. Θεσσαλονίκη, 1992

6. Weiss E., Bray P., Tayback M.: A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. N. Engl. J. Med. 334: 1090-1094 (1996)

7. Walter D., Schachinger V. Elsner M., Dimmeler S., Zeiher A.: Platelet glycoprotein IIIa polymorphism and risk of coronary stent thrombosis. Lancet 350: 1189-1190 (1997)

8. O’Reilly R.: Drugs used in disorder of coagulation. In (Katzung B., Ed) Basic and Clinical Pharmacology. Pp. 507-521, Prentice-Hall Intern.Inc. Con., USA, 1995

9. Savi P., Heilmann E., Nurden P.: Clopidogrel; an antithrombotic drug acting on the ADP-dependent activation pathway of human platelets. Clin. Appl. Thromb. 2: 35-42 (1996)

10. Μακρής Π.: Αιμόσταση. Θεσ/νίκη, 1994

11. Χριστοπούλου-Κόκκινου Β: Υπερπηκτικότητα και θρόμβωση. Γρ. Παρισιάνος, Αθήνα, 1996

12. Easton J.: Benefit of clopidogrel in patients with evidence of cerebrovascular disease. Neurology 50(Suppl.3): 33 (1998)

13. Libby P.: Molecular basis of the acute coronary syndromes. Circulation 91: 2844-2850 (1995)

14. Davie E., Fujikawa K., Kisiel W.: The coagulation cascade: initiation, maintenance and regulation. Biochemistry 30: 10363-10370 (1991)

15. Majerus Ph., Broze G., Miletich J., Tollefsen D.: Anticoagulant, thrombolytic and antiplatelet drugs. In: (Hardman J. et al., eds) Goodman and Gilman’s. The Pharmacological Basis of Therapeutics. Pp. 1343-1359, McGraw-Hill, New York, 1996

16. O’Reily R: Warfarin metabolism and drug-drug interactions. Adv. Exp. Med. Biol. 214: 205-212 (1987)

17. Laurence D., Bennet P.: Clinical Pharmacology. Pp. 567-582, Churchil Livingstone, London, 1987

18. Handin R.: Anticoagulant, fibrinolytic and antiplatelet therapy. In: (Wilson J. et al., eds) Harrisson. Principles of Internal Medicine. Pp. 1511-1523, McGraw-Hill Inc., New York, 1991

19. Παραδέλλης Α.: Αλληλεπιδράσεις φαρμάκων, University Studio Press , Θεσσαλονίκη 1990

20. G. Gibbons G.: Homeostatic balance between angiotensin II and nitric oxide. Clin. Cardiology, 20(Suppl.II) 18-24, 1997

21. H. Cooke J.: Endothelium as a target organ. Clin. Cardiol. 20(Suppl.II): 45-51 (1997)

22. Παπαδόπουλος Κ.: Δυσλειτουργία ενδοθηλίου και υπερθρομβωτικότητα. Γαληνός 37: 23-31 (1995)

23. Schoming A., Neumann F., Kastrati A.: A randomized comparison of antiplatalet and anticoagulant therapy after the placement of coronary artery stents. N. Engl. J. Med. 334: 1084-1089 (1996)

24. Marcus A.: platelet activation.In: (Fuster V., Ross R., Topol E., Eds) Atherosclerosis and Coronary Artery Disease.Pp. 607-637, Lippincott-Raven, New York, 1996

25. Παπαδόπουλος Κ.: Αθηρογένεση, αρτηριοσκλήρωση και δυσλειτουργία του ενδοθηλίου. Επιθ. Κλιν. Φαρμακολ. Φαρμακοκιν. 13: 33-43 (1995)

26. Handin R., Loscalo J.: Hemostasis, thrombosis, fibrinolysis and cardiovascular disease. In: (Braunwald, ed) Heart Disease. Pp. 1758-1781, Saunders, Philadelphia, 1988

27. Luscher T. and Barton M.: Biology of the endothelium. Clin. Cardiol. 20(Suppl.II): 3-10 (1997)

28. Capri Steering Committee. A randomised blind trial of clopidogrel versus aspirin in patients at risk of ischaemic events. Lancet 348: 1329-1339 (1996)

29. Gent M.: Benefit of clopidogrel in patients with coronary disease. Circulation 96(Suppl.1): 467 (1997)

30. Hourani S., Hall D.: Receptors for ADP on human blood platelets. Trends Pharmacol. Sci. 15: 103-107 (1994)

31.Little J. and Falace D.: Dental management of the medically compromised patient.  Boston. Mosby, 1993

32. Barber A., Green D., Galluzzo T., Tsao C.: The bleeding time as a preoperative screening test. Am. J. Med. 78: 761-765 (1985)

33. Benoliet R.: Dental treatment for the patient on anticoagulant therapy prothrombin time.What difference does it make? Oral Surg. 62: 149-151 (1986)

34. Shater W., Hine M., Levy B.: A textbook of Oral Pathology. Saunders, Philadelphia, 1983

35. Sindet Petersen S.: Haemostasis in oral surgery. Dan. Med. Bull. 38: 427-443 (1994)

36. Ublansky H.:Comprehensive dental care for children with bleeding disorders. J. Can. Dent. Assoc. 5802: 111-114 (1992)

37. Windrope M, Lee G., Boggs D.: Clinical hematology. Lea and Febiger, Philadelphia, 1981

38. Zieve P.: Bleeding disorders. In: (Harvey A et al., eds) The Principles and Practice of Medicine. Appleton, New York, 1976